Skip to main content
. 2016 Jun;41(6):388–390.

Table 1.

Available Biologic Therapies for Patients With Moderate-to-Severe Plaque Psoriasis35–37

Drug Name
Company 		Therapeutic Class FDA Approval
Adalimumab (Humira)
AbbVie 		IgG1 mAb (TNFα inhibitor) 2008
Etanercept (Enbrel)
Amgen 		Dimeric fusion protein (TNFα and TNFβ inhibitor) 2004
Infliximab (Remicade)
Janssen 		IgG1/κ mAb (TNFα inhibitor) 2006
Infliximab-dyyb (Inflectra)
Celltrion/Hospira 		Biosimilar to infliximab 2016
Ixekinumab (Taltz)
Eli Lilly 		IgG4 mAb (IL-17A inhibitor) 2016
Secukinumab (Cosentyx)
Novartis 		IgG1/κ mAb (IL-17A inhibitor) 2015
Ustekinumab (Stelara)
Janssen 		IgG1/κ mAb (IL-12/23 p40 subunit inhibitor) 2009

IgG = immunoglobulin G; IL = interleukin; mAb = monoclonal antibody; TNF = tumor necrosis factor.